Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma :natural progression and management

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 8, 2018, Pages 760-765

  Huffman, Brandon M ^a   Kottschade, Lisa A ^a   Kamath, Patrick S ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

adverse drug event; Hepatotoxicity; immune checkpoint antibody; melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORINE; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMEN; ABDOMINAL PAIN; ADRENAL GLAND; ADULT; ADVERSE EVENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CONFUSION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOPHYSITIS; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PAROTID GLAND; PNEUMONIA; RASH; RETROSPECTIVE STUDY; SUBCUTANEOUS TISSUE; SYSTEMIC THERAPY; TESTIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; DISEASE EXACERBATION; DISEASE MANAGEMENT; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TOXIC HEPATITIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CTLA-4 ANTIGEN; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 85026420488     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000374     Document Type: Article

References (17)

1. United States Department of Health and Human Services, Center for Disease Control: United States Cancer Statistics Working Group. United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. Available at: http://www.cdc.gov/ uscs. Accessed May 24, 2016.
2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23-34.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372: 2521-2532.
4. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16:375-384.
5. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
6. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
7. Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015;166: 412-424.
8. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013;31:1071-1077.
9. Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. Am J Surg Pathol. 2015;39:1075-1084.
10. Weber JS, Dummer R, De Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675-1682.
11. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
12. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190-209.
13. Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198.
14. Yousaf N, Davidson M, Goode E, et al. The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res. 2015;25: 259-264.
15. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
16. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043-6053.
17. United States National Library of Medicine. Liver Toxicity: Levetiracetam. 2016. Available at: https://livertox.nlm.nih.gov/ Levetiracetam.htm. Accessed October 31, 2016.